Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, has secured $600 million in funding from investors.
The financing round, led by Bain Capital's private equity group, included Royalty Pharma, the sovereign wealth fund in Qatar, and the asset manager of Canada's national pension plan. Existing investors also participated in the funding.
- The deal highlights the ongoing interest in weight loss drugs.
- Kailera's Series B round comes almost a year after its launch with $400 million.
- The funding follows Pfizer's announcement to acquire Metsera, another obesity drug developer, for $4.9 billion.
The persistent attention to weight loss drugs remains, despite years of activity and some clinical disappointments.
Author's summary: Kailera Therapeutics raises $600 million in funding.
More News
- Big Bash League upcoming match schedule
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- [Luke Skywalker - Wikipedia summary]
- Ryder — Founder and Leader of the PAW Patrol Team
- Hockey30 | Le Mouton Noir du Hockey
- Katy Perry en couple avec Justine Trudeau : l’ex-Premier ministre la regarde
- [Transaction majeure pour un top-6 : c'est confirmé pour trois nom chez le Canadien]
- DansLesCoulisses.com | Pour en savoir plus que les autres!
- Tom & Luke Low Carb Snackaballs recall
- The 400 million reasons behind Cricket Australia’s Big Bash sale